Combined therapy with anticoagulation and glucocorticoids plus plasma exchange and/or intravenous immunoglobulins improves the survival rate of patients with catastrophic antiphospholipid syndrome (APS), according to data from an international registry. Triple therapy was associated with a higher chance of survival in comparison with treatment with other combinations of the drugs included in the triple therapy (adjusted OR 1.7, 95% CI 1.2–2.6) or treatment with none of those drugs (adjusted OR 9.7, 95% CI 2.3–40.6).
References
Original article
Rodríguez-Pintó, I. et al. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Rheumatology. https://doi.org/10.1093/rheumatology/key082 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onuora, S. Triple therapy boosts survival in catastrophic APS. Nat Rev Rheumatol 14, 320 (2018). https://doi.org/10.1038/s41584-018-0017-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-018-0017-5
